Table 3. Adverse events recorded within day 0 to day 3 after MDA using dihydroartemisinin-piperaquine.
| Adverse event | Month | Day 0 | Day 1 | Day 2 | Overall | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number taking drug | Number of events | Percent of events | Number taking drug | Number of events | Percent of events | Number taking drug | Number of events | Percent of events | Number of doses taken | Number of events | Percent of events | ||
| Vomiting | M0 | 6,866* | 51 | 0.74% | 6,769 | 26 | 0.38% | 6,721 | 6 | 0.09% | |||
| M1 | 6,583 | 8 | 0.12% | 6,454 | 11 | 0.17% | 6,389 | 4 | 0.06% | 59,375 | 121 | 0.20% | |
| M2 | 6,583 | 12 | 0.18% | 6,518 | 3 | 0.05% | 6,492 | 0 | 0.00% | ||||
| Dizziness† | M0 | NA | NA | NA | 4,690 | 176 | 3.75% | 4,680 | 129 | 2.76% | |||
| M1 | NA | NA | NA | 4,285 | 87 | 2.03% | 4,247 | 55 | 1.30% | 26,898 | 586 | 2.18% | |
| M2 | NA | NA | NA | 4,505 | 86 | 1.91% | 4,491 | 53 | 1.18% | ||||
| Itching† | M0 | NA | NA | NA | 4,690 | 3 | 0.06% | 4,680 | 6 | 0.13% | |||
| M1 | NA | NA | NA | 4,285 | 0 | 0.00% | 4,247 | 1 | 0.02% | 26,898 | 12 | 0.04% | |
| M2 | NA | NA | NA | 4,505 | 0 | 0.00% | 4,491 | 2 | 0.04% | ||||
*The tolerability data included villages that had MDA but no follow-up (Cambodia and Lao People’s Democratic Republic after M12).
†No recorded data from Vietnam for dizziness and itching; data from 1 deferred MDA village from Cambodia included.
M[number], month [number]; MDA, mass drug administration; NA, not applicable.